Handelsavisen
prelaunch
Companies Healthcare RUBI.NS
RU
RUBI.NS NSE (India) Biotechnology & Life-Science Tools

Rubicon Research Ltd

$944,55
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
17,1 %
ROE
24,8 %
Net margin
10,5 %
Debt / equity
0,77
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Rubicon Research Ltd is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic products and services.

Business. Rubicon Research Ltd (RUBI.NS) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target910,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
910,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
24,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RUBI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RUBI.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Rubicon Research Ltd (RUBI.NS) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    Rubicon Research Ltd maintains a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 1.35, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. The company's cash and equivalents amount to INR 1,162.09 million, while its long-term debt stands at INR 4,176.11 million, resulting in a net cash position that is negative after subtracting total debt.

    In terms of profitability, Rubicon Research Ltd demonstrates a return on equity (ROE) of 24.84% and a return on assets (ROA) of 9.26%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of INR 2,193.58 million and net income of INR 1,343.61 million reflect a healthy margin structure, which is in line with the industry's preferred metrics for profitability.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risk if the segment or region experiences a downturn.

    Looking ahead, Rubicon Research Ltd is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of INR -702.24 million indicates a reduction in investment in physical assets, which may be a strategic decision to preserve cash or a sign of a mature business with fewer expansion opportunities.

    The risk assessment for Rubicon Research Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing. However, the low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, preserving the value of existing shareholders' equity.

    Recent events and filings do not indicate any material changes in the company's operations or financial strategy. The company's strong buy recommendation from analysts, with a mean price target of INR 910.00, suggests a positive outlook from the investment community.

    Key takeaways
    • Rubicon Research Ltd has a strong return on equity (24.84%) and a healthy return on assets (9.26%), indicating efficient use of capital.
    • The company's liquidity position is moderate, with a current ratio of 1.35 and a net cash position that is negative after subtracting total debt.
    • The company's revenue is concentrated in a single business segment, which may increase its exposure to market-specific risks.
    • Analysts have a positive outlook on the company, with a mean price target of INR 910.00 and a strong buy recommendation.
    • The company is not expected to issue a significant number of new shares in the near term, preserving the value of existing shareholders' equity.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $944,55
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $5.41B
    Net cash
    -$3.01B
    Current ratio
    1.4
    Debt / equity
    0.8
    ROA
    9.3%
    ROE
    24.8%
    Cash conversion
    118.0%
    CapEx / revenue
    -5.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target$910,00 · Median $910,00
    Low $865,00High $955,00
    Operating income · consensus3,3B INR

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$865,00
    Mean$910,00
    Median$910,00
    High$955,00
    Spot$944,55
    −3.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin17,1 %Above P75
    Net Margin10,5 %Above P75
    ROE24,8 %Above P75
    Capex / Rev-5,5 %Below median
    D/E0,77Bottom quartile
    Cash Conv1,18Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Rubicon Research Ltd Market data — financials · 2026-05-29
    • Rubicon Research Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    5.1Kshares short-75.1% vs prior
    1days to cover
    61.0%short of daily vol
    4fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RUBI.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 11.3%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 34.2%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.70xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.93xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 241.4%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -89.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -89.2%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 8.6%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 7.9%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -0.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -2.8%Derived (calculated)
    • Revenue (annual): USD 23.52MSEC XBRL filing
    • Total assets (annual): USD 134.07MSEC XBRL filing
    • Shareholders' equity (annual): USD 45.8MSEC XBRL filing
    • Operating income (annual): USD 12.4MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES 49SEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES 49SEC XBRL filing
    • Operating cash flow (annual): USD 11.33MSEC XBRL filing
    • Long-term debt (annual): USD 82.28MSEC XBRL filing
    • Shares outstanding (annual): 385.5KSEC XBRL filing
    • Cash & equivalents (annual): USD 3.96MSEC XBRL filing
    • Current assets (annual): USD 7.05MSEC XBRL filing
    • Current liabilities (annual): USD 10MSEC XBRL filing
    Showing 24 of 40 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-03 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-07-03EVENTQ3 2026 earnings (expected) estimated date
    2026-06-26 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-06-26EVENTQ2 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage